Our Structural Heart capabilities include screening for appropriate care across aortic stenosis, aortic regurgitation, mitral stenosis, mitral regurgitation, tricuspid regurgitation, and pulmonary regurgitation.

Within cardiomyopathies, our screening protocols address care across non-ischemic dilated cardiomyopathy, hypertrophic cardiomyopathy, cardiac amyloidosis, pulmonary hypertension, and cardiac oncologic disease. Our mission is to shorten the time to referral for consideration of advanced heart failure treatment options like LVAD or heart transplants. We also aim to enable clinicians to track patient adherence to prescribed diagnostic studies and follow-up visits with cardiologists.

Our electrophysiology capabilities include screening for risk of sudden cardiac arrest (SCA), risk of left atrial appendage thrombus, and atrial fibrillation. SCA causes over 300,000 deaths annually in the United States; however, prevention is challenging due to difficulty identifying at-risk patients.² Less than 10% of patients who meet the AHA/ACC/HRS guidelines criteria for a primary prevention implantable cardioverter-defibrillator (ICD) receive a device, with women more likely to be undertreated.² Tempus Next  continuously monitors patient data to find at-risk patients, and alert the patient’s care team of any needed follow-up or disease progression.

Tempus Next also screens for an array of additional conditions including congestive heart failure, acute coronary syndrome, ischemic heart diseases, hypertension, and dyslipidemia. Our program monitors length of time and patient adherence to Guideline Directed Medical Therapy, as well as key markers including ejection fraction during this period to determine the potential need for referral to a heart clinic. Studies have shown that patients not optimized on Guideline Directed Medical Therapy are 26% more likely to have higher annualized healthcare utilization and emergency department visits.³